Tarsus Pharmaceuticals Inc. (TARS): Price and Financial Metrics

Tarsus Pharmaceuticals Inc. (TARS): $17.44

0.33 (-1.86%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

D

Add TARS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#320 of 356

in industry

TARS Price/Volume Stats

Current price $17.44 52-week high $25.25
Prev. close $17.77 52-week low $11.33
Day low $17.10 Volume 405,600
Day high $17.91 Avg. volume 249,110
50-day MA $17.39 Dividend yield N/A
200-day MA $16.00 Market Cap 568.84M

TARS Stock Price Chart Interactive Chart >

TARS POWR Grades

  • TARS scores best on the Value dimension, with a Value rank ahead of 47.25% of US stocks.
  • The strongest trend for TARS is in Growth, which has been heading down over the past 177 days.
  • TARS ranks lowest in Growth; there it ranks in the 2nd percentile.

TARS Stock Summary

  • TARS's went public 2.95 years ago, making it older than only 12.03% of listed US stocks we're tracking.
  • With a price/sales ratio of 44.23, TARSUS PHARMACEUTICALS INC has a higher such ratio than 96.47% of stocks in our set.
  • Revenue growth over the past 12 months for TARSUS PHARMACEUTICALS INC comes in at -28.14%, a number that bests merely 9.18% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to TARS, based on their financial statements, market capitalization, and price volatility, are ASTC, FUV, CERS, DMRC, and CHRS.
  • TARS's SEC filings can be seen here. And to visit TARSUS PHARMACEUTICALS INC's official web site, go to www.tarsusrx.com.

TARS Valuation Summary

  • TARS's price/sales ratio is 44.2; this is 2226.32% higher than that of the median Healthcare stock.
  • Over the past 36 months, TARS's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for TARS.

Stock Date P/S P/B P/E EV/EBIT
TARS 2023-09-22 44.2 3.7 -6.1 -5.3
TARS 2023-09-21 44.1 3.7 -6.1 -5.3
TARS 2023-09-20 43.7 3.7 -6.0 -5.3
TARS 2023-09-19 44.4 3.8 -6.1 -5.4
TARS 2023-09-18 43.2 3.7 -5.9 -5.2
TARS 2023-09-15 42.1 3.6 -5.8 -5.0

TARS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TARS has a Quality Grade of B, ranking ahead of 79.3% of graded US stocks.
  • TARS's asset turnover comes in at 0.335 -- ranking 138th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows TARS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.335 0.963 -0.432

TARS Price Target

For more insight on analysts targets of TARS, see our TARS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $53.80 Average Broker Recommendation 1.1 (Strong Buy)

Tarsus Pharmaceuticals Inc. (TARS) Company Bio


Tarsus is a clinical-stage biopharmaceutical company headquartered in Irvine, California. Tarsus was founded in 2017 to bring innovative therapies to a range of diseases in need of better solutions, starting with Demodex blepharitis and eye care.


TARS Latest News Stream


Event/Time News Detail
Loading, please wait...

TARS Latest Social Stream


Loading social stream, please wait...

View Full TARS Social Stream

Latest TARS News From Around the Web

Below are the latest news stories about TARSUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TARS as an investment opportunity.

Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis

IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, MD, PhD, Chief Executive Officer and Chairman, will ring the closing bell at the Nasdaq Stock Market on Wednesday, September 6, 2023. The event marks the launch of XDEMVY™, which is now available at pharmacies nationwi

Yahoo | September 6, 2023

Tarsus to Present at Upcoming Investor Conferences

IRVINE, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Strategy Officer, will participate in the following conferences, both located in New York City, NY: H.C. Wainwright 25th Annual Glo

Yahoo | August 30, 2023

15 Most Shorted Stocks That Are Loved By Analysts

In this piece, we will take a look at the 15 most shorted stocks that are loved by analysts. If you want to skip our introduction to short selling, then jump ahead to 5 Most Shorted Stocks That Are Loved By Analysts. Short selling is a tricky game. Rapid share price appreciations can stretch a […]

Yahoo | August 28, 2023

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available via prescription from an eye care provider Sales force deployed, calling on ophthalmologists and optometrists nationwide IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology

Yahoo | August 24, 2023

Insider Spends US$160k Buying More Shares In Tarsus Pharmaceuticals

Investors who take an interest in Tarsus Pharmaceuticals, Inc. ( NASDAQ:TARS ) should definitely note that the Chief...

Yahoo | August 19, 2023

Read More 'TARS' Stories Here

TARS Price Returns

1-mo 4.68%
3-mo -1.02%
6-mo 38.74%
1-year 2.59%
3-year N/A
5-year N/A
YTD 18.96%
2022 -34.84%
2021 -45.56%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!